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Inferior vena cava filters in malignant disease
Beth P. Jarrett, MD, Matthew J. Dougherty, MD, and Keith D. Calligaro, MD, Philadelphia, Pa
Purpose: Patients undergoing treatment for cancer have a high risk and prevalence of venous thrombosis and frequent
contraindications to anticoagulation therapy that lead to placement of caval filters. We questioned whether the increasing
frequency of this intervention has clinical benefit.
Methods: Between 1993 and 2000, 116 patients undergoing active treatment for malignant disease underwent filter
placement at our institution. Outcome was retrospectively assessed with regard to procedural complications, recurrent
thrombotic events, and patient survival.
Results: Primary tumors were gastrointestinal (n  25), lung (n  24), breast (n  14), gynecologic (n  14), prostate
(n  12), hematologic (n  8), urologic (n  4) or other (n  15). Indications for filter were contraindication to
anticoagulation therapy for deep venous thrombosis (DVT) or pulmonary embolism (PE; bleeding, n 33; surgery, n
29), recurrent or propagating DVT or recurrent PE during anticoagulation therapy (n 17), right heart failure (n 15),
intracerebral malignancy (n  7), and other indications (n  18). Procedural complications were five localized
hematomas, none necessitating surgery. Two patients had progressive DVT and three had clinical recurrent PE after filter
placement. Life-table analysis revealed survival rates of 68.8% at 30 days, 49.4% at 3 months, and 26.8% at 1 year
(standard error, <5%). Of 91 patients with stage IV disease, 42 patients had died of cancer within 6 weeks and only 13.7%
were alive at 1 year.
Conclusion: Although recurrent thromboembolic events are rare after caval filter placement in patients with malignant
disease, survival is short in most patients with stage IV disease and prevention of PE may be of little clinical benefit and
a poor utilization of resources. Oncologists should consider these sobering results when requesting filter placement in
patients with advanced malignant disease. (J Vasc Surg 2002;36:704-7.)
Malignant disease as an independent risk factor for
deep venous thrombosis (DVT) and pulmonary embolism
(PE) is well recognized. In fact, up to 10% of patients with
DVT and 20% of patients with PE will prove to harbor
malignant disease.1,2 A hypercoagulable state that is poorly
understood exists in these patients. Theories include the
increased synthesis of procoagulant factors by tumor cells
or the monocyte/macrophage cell line.3 Abnormally high
platelet aggregation has been identified in patients with
tumor and appears to correlate with metastatic potential, a
potential reason for the association of DVT and cancer.4 A
debate continues in the literature regarding the appropriate
treatment for thromboembolic disease (TED) in this pa-
tient population. Whether initial anticoagulation therapy or
immediate caval filter placement is the best strategy is an
evolving discussion. The purpose of this study was to
examine the clinical benefit of placement of inferior vena
cava (IVC) filters in patients with cancer who have contra-
indications to or who have failed standard anticoagulation
therapy or in whom filters are placed for other indications.
METHODS
The medical records of all patients with discharge diag-
noses of tumor and IVC filter placement between 1993 and
2000 at Pennsylvania Hospital were reviewed. In all, 137
patients who were being treated for tumor or malignant
disease at the time of filter placement were identified.
Twenty-one of these patients were excluded for benign
tumors or for inadequate documentation of a thromboem-
bolic event. Diagnosis of TED in the cohort was made with
duplex scan or venography for DVT and with ventilation-
perfusion scanning, pulmonary arteriography, computed
tomographic scanning, or echocardiography for PE. Pa-
tient medical records were reviewed for complications of
filter placement and recurrent thromboembolic events. Re-
current thromboembolic events were considered to have
occurred with documentation of extension of thrombosis
or new contralateral thrombosis for DVT or with new
perfusion defect on ventilation-perfusion scan or pulmo-
nary arteriogram for PE. Repeat diagnostic studies were
performed only in patients with new or worsening symp-
toms of PE or DVT. Charts were reviewed for survival data.
The cancer registry, office notes, and morgue records were
used to gain additional survival data. Mortality data were
evaluated with life-table analysis.
RESULTS
The mean age for the cohort of 116 patients was 66.7
years (range, 26 to 91 years). Seventy females and 46 males
were included. Tumor type for the study group varied
widely but in an expected distribution. The largest group of
tumors were of gastrointestinal origin (n  25; 21.6%),
followed by lung (n 24; 20.7%), breast (n 14; 12.1%),
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gynecologic (n  14; 12.1%), prostate (n  12; 10.3%),
hematologic (n  8; 6.9%), genitourinary (n  4; 3.4%)
and other cancers (n  15; 12.9%). Indications for filter
placement were contraindication to anticoagulation ther-
apy for DVT or PE (bleeding, n  33; recent or planned
surgery, n  29), recurrent or propagating DVT or recur-
rent PE during anticoagulation therapy (n  17), right
heart failure (n 15); intracerebral malignant disease (n
7), and other indications (n  18). Most patients in the
group had evidence of metastatic disease (stage IV) at the
time of filter placement (n  91; 78.4%). Twenty-one
patients with local disease (stage I or stage II) comprised
17% of the group, and four patients (3.7%) had regional
disease (stage III).
Filter types used were at the surgeon’s discretion and
consisted of the Greenfield device (Meditech, Boston Sci-
entific, Watertown, Mass) in 101 patients, the Simon Niti-
nol filter (Bard, Woburn, Mass) in nine patients, and the
Venatech filter (Braun, Aesculap, Tuttlingen, Germany) in
six patients. Filters were deployed via a femoral approach in
44 patients and via a jugular approach in 72. Postproce-
dural complications included five localized hematomas
(4.3%), none of which necessitated surgical intervention.
No other complications occurred as a result of filter deploy-
ment. In late follow-up, two patients were diagnosed with
progressive or recurrent DVT (1.7%). Three additional
patients had symptomatic recurrence of PE (2.6%). The
mean follow-up period after filter placement was 12.2
months. Life-table analysis revealed overall survival rates of
68.8% at 30 days and 57.4% at 3 months (Fig 2). The 1-year
survival rate for all cancer stages was 26.8% (standard error,
5%). Survival rates were significantly worse for patients
with stage IV disease than for patients with earlier stage
disease. For patients with stage IV disease, 48% had died
within 6 weeks. The 1-year survival rate with stage IV
cancer was only 13.7%, compared with 77.9% for earlier
stages. Life-table comparison for these groups is depicted in
Fig 3.
DISCUSSION
Bleeding complication rates in patients treated with
anticoagulation therapy who have cancer have been re-
ported to be as high as 35% to 50%.5,6 Because long-term
studies have shown IVC filter placement to be safe and
effective at prevention of PE,7-9 we and other authors have
previously suggested primary IVC filter placement for pa-
tients with malignant disease.5,10 Our recommendation
was made on the basis of experience with 30 patients with
stage III and IV cancer, in whom 15 of 20 treated with
primary anticoagulation therapy had bleeding complica-
tions or inadequate anticoagulation and progressive TED.
However, other investigators have shown anticoagulation
therapy to be reasonably safe in most patients with can-
cer,11,12 and with better therapeutic monitoring, the rate of
bleeding complications has dropped to 13% to 19%.11-13
Most clinicians therefore reserve filters for failures and
complications of anticoagulation therapy.
Fig 1. Indications for filter placement.
Fig 2. Overall survival rates after filter placement. Patients at risk
depicted on survival curve.
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The focus of this study was not to evaluate primary filter
placement compared with primary anticoagulation therapy
as in our prior report5 but rather to look at outcome in
patients who were treated with filters for commonly ac-
cepted reasons. The rate of recurrent venous thromboem-
bolic events after filter placement varies from 4.2% to 62%
in the literature.5,6,13-16 A recent study of such events in
patients with cancer describes a 30.7% incidence rate of
DVT and a 1.8% rate of PE recurrence with scheduled
surveillance.9 Cohen, Grella, and Citron14 reported only
4.8% of patients having recurrent TED events when no
routine surveillance was performed, similar to the 4.3%
symptomatic recurrence rate in our series. Of course, ag-
gressive surveillance would reveal a higher TED recurrence
rate, but asymptomatic events are unlikely to become clin-
ically significant in this population. The mortality rate from
recurrent PE is not described in these reports but may be as
high as 10%.17
The idea that advanced staged cancer may not warrant
aggressive therapy for TED is not new. Previous authors
have proposed a conservative approach when evaluating
patients with stage IV disease for IVC filter placement or
even anticoagulation therapy.18,19 Several studies report
dismal survival data for such patients and discourage inter-
vention. Rosen, Porter, and Kim19 observed death during
hospitalization or within 3 weeks of discharge in 16 of 61 of
patients (26%) with TED with malignant disease, even
higher (46%) with suprainguinal thrombus, leading the
authors to question the value of filters in this setting. In
their retrospective review, Ihnat et al11 reported no differ-
ence in mortality rates between anticoagulation therapy
and filter placement in patients with malignant disease—
38% and 42%, respectively, at 3 months. Our 31.2% 30-day
mortality rate was similar to that observed by Walsh et al18
(24% at 2 months). However, the more compelling 48%
6-week mortality figure for patients with stage IV disease
suggests that metastatic malignant disease in patients with
TED is an especially strong harbinger of imminent mortal-
ity, as others have suggested.19
The cost of filter placement versus anticoagulation
therapy has been evaluated. A large metaanalysis by Sarasin
and Eckman20 with Markov modeling concluded that
treatment results for TED in malignant disease with anti-
coagulation therapy versus filter placement are roughly
equivalent, with improvements in quality-adjusted life years
in the range of 10% to 20% compared with no treatment.
However, the cost of filter placement (approximately
$5000)21 may be less than anticoagulation therapy because
of the added costs of treating bleeding complications of
anticoagulation therapy.20 Low–molecular weight heparins
have been shown to be as safe as unfractionated heparins in
the management of TED, with improvement in survival in
patients with TED with cancer.22 The availability of low–
molecular weight heparin therapy for outpatient treatment
of TED complicates cost analysis because a significant
contributor to cost is the need for hospitalization. Even if
one accepts the assumptions of the Markov models,
whether the marginal clinical benefit of either anticoagula-
tion or filter placement is worth the cost remains debatable.
Because approximately one in seven patients with stage
IV cancer in our series did survive at least 1 year (numbers
were too small for later survival figures), the pertinent
questions are: 1, what clinical benefit is provided by the
filter in this subgroup; and 2, what is the best way to
identify those patients who may survive long enough to
derive the benefit? The latter question is best answered by
thoughtful consideration of the patient’s overall status by
the oncologist and treating physicians. In the half of pa-
tients who survived less than 6 weeks, that filter placement
was clinically beneficial is hard to conceive, and clearly a
cost analysis would even more strongly question utility. We
noted a large proportion of patients (25%) in whom the
contraindication to anticoagulation therapy was transient
(ie, for a few days after surgery). Delaying initiation of
anticoagulation therapy until it is safe may be a reasonable
strategy for some patients. The basis for presuming that
Fig 3. Survival comparison for stage IV versus earlier stages.
Log-rank test, P  .001. Standard error, 10%, through 60
months for stage IV and through 15 months for stages I, II, and
III.
Survival summary table for stage IV versus stages I, II, and III
No. observed No. of events No. censored Percent censored No. missing No. invalid
Stages I, II, and III 25 11 14 56.000% 0 0
Stage IV 91 82 9 9.890% 0 0
Total 116 93 23 19.828% 0 0
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anticoagulation therapy cannot be tolerated in individual
patients must constantly be reviewed.
CONCLUSION
Our review suggests that, for patients in the advanced
stages of cancer (stage IV) with TED who have a contrain-
dication to anticoagulation therapy, nontreatment should
be considered a reasonable alternative to filter placement.
Likewise, in patients in whom TED develops despite anti-
coagulation therapy, more aggressive anticoagulation ther-
apy or simply continuation of anticoagulation therapy may
be preferable to filter placement. Because filter placement
carries minimal morbidity and simplifies management of
these patients, its use has been growing, but cost and
likelihood of benefit considerations are appropriate here.
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